Valuation: Ind-Swift Laboratories Limited

Market Cap 1.14TCr 12Cr 10Cr 9.61Cr 8.83Cr 17Cr 17Cr 114.46Cr 45Cr 554.75Cr 44Cr 43Cr 1.93TCr P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 713.1Cr 7.39Cr 6.47Cr 6.02Cr 5.52Cr 10Cr 11Cr 72Cr 28Cr 347.12Cr 28Cr 27Cr 1.2TCr EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
40.72%
Yield 2024 *
-
Yield 2025 -
1 day-1.91%
1 week+1.40%
Current month+14.51%
1 month+24.38%
3 months+61.92%
6 months+119.30%
Current year+164.40%
1 week 224
Extreme 224
240.39
1 month 189.31
Extreme 189.31
248.45
Current year 87.25
Extreme 87.25
248.45
1 year 87.15
Extreme 87.15
248.45
3 years 68.72
Extreme 68.72
248.45
5 years 52.65
Extreme 52.65
248.45
10 years 15
Extreme 15
248.45
Manager TitleAgeSince
Chief Executive Officer 74 04/01/1995
Chief Executive Officer 43 15/06/2011
Director of Finance/CFO - 29/09/2018
Director TitleAgeSince
Director/Board Member 43 -
Chairman 74 -
Director/Board Member 35 23/03/2010
Date Insider Type Main position Quantity % Market Cap.
12/09/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
-1.91%+1.40%+119.86%+153.47% 21Cr
-0.96%+0.02%+14.81%+77.10% 4.89TCr
-0.99%-0.27%+66.69%+108.95% 3.57TCr
-1.21%-1.60%-3.99%+34.91% 1.2TCr
-1.47%-0.64%+16.11%+83.68% 1.18TCr
-0.37%+0.94%+34.42%+136.73% 895.32Cr
+0.33%-1.13%+50.36%-5.96% 691.16Cr
-0.34%-2.41%+14.20%+33.03% 677.9Cr
-1.88%-4.56%+0.69%+192.09% 656.98Cr
-2.47%-5.28%-33.67%+6.76% 580.84Cr
Average -1.13%-1.66%+27.95%+82.08% 1.44TCr
Weighted average by Cap. -1.01%-0.35%+26.70%+82.20%

Financials

2024 2025
Net sales 1.3TCr 13Cr 12Cr 11Cr 10Cr 19Cr 19Cr 130.29Cr 51Cr 631.47Cr 50Cr 49Cr 2.19TCr 561.71Cr 5.82Cr 5.1Cr 4.74Cr 4.35Cr 8.2Cr 8.32Cr 56Cr 22Cr 273.42Cr 22Cr 21Cr 949.11Cr
Net income 420.96Cr 4.36Cr 3.82Cr 3.55Cr 3.26Cr 6.14Cr 6.24Cr 42Cr 17Cr 204.91Cr 16Cr 16Cr 711.29Cr 250.48Cr 2.59Cr 2.27Cr 2.11Cr 1.94Cr 3.65Cr 3.71Cr 25Cr 9.83Cr 121.92Cr 9.74Cr 9.53Cr 423.22Cr
Net Debt -415.31Cr -4.3Cr -3.77Cr -3.5Cr -3.22Cr -6.06Cr -6.15Cr -42Cr -16Cr -202.16Cr -16Cr -16Cr -701.73Cr -426.55Cr -4.42Cr -3.87Cr -3.6Cr -3.3Cr -6.22Cr -6.32Cr -43Cr -17Cr -207.63Cr -17Cr -16Cr -720.73Cr
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Date Price Change Volume
22/26/22 ₹233.07 -1.91% 4,47,639
21/26/21 ₹237.60 +1.54% 2,71,232
20/26/20 ₹233.99 +1.09% 4,38,766
17/26/17 ₹231.47 -1.03% 2,88,534
16/26/16 ₹233.89 +3.12% 5,62,319
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock